The weight loss medications landscape in the UAE is moving fast. Since we first published this article in October 2025, three themes have accelerated globally and across Dubai and Abu Dhabi:
-
More powerful next-generation injections
-
A real shift toward tablets and less-frequent dosing
-
Tighter scrutiny around safety, supply, and non-approved “copies” of GLP-1 medicines
Below is a fully updated 2026 overview of the most important weight loss medications in the UAE, what is already available through licensed providers, and what is coming next.
What Changed Since October 2025?
The biggest developments in medical weight loss include:
• Oral GLP-1 weight-loss therapy arrived in the US. Novo Nordisk’s Wegovy pill was approved in late December 2025, marking the first true “no-injection” GLP-1 era. UAE availability depends on MoHAP, DHA, and DOH approval timelines.
• CagriSema progressed further, with strong obesity data from REDEFINE-1 and new late-stage results in people with type 2 diabetes.
• The industry is pushing toward monthly or even quarterly dosing, while regulators are tightening control over unsafe supply chains and compounded copies.
For patients searching for new weight loss injections in Dubai or upcoming oral alternatives, 2026 is a pivotal year.
Today’s Leading Weight Loss Medications in the UAE
These treatments are currently available through licensed medical providers
Tirzepatide (Mounjaro / Zepbound)
Tirzepatide is a dual-action medicine (GLP-1 + GIP). In the SURMOUNT-5 study, tirzepatide produced greater average weight loss at 72 weeks than semaglutide in patients with obesity and no diabetes.
In real-world clinics across the UAE, results depend heavily on:
• Careful dose titration
• Side-effect management
• Structured nutritional follow-up
When properly supervised, tirzepatide remains one of the most effective GLP-1 weight loss options in Dubai.
Semaglutide (Wegovy) — And The New Pill Era
Semaglutide remains a cornerstone of weight loss medication in Dubai and Abu Dhabi.
The major 2026 development is convenience: an oral Wegovy pill was approved in the US in December 2025, potentially widening access for patients who prefer not to inject.
However, in the UAE, medication rollout depends on:
• Regulatory approval
• Supply chain stability
• Local prescribing frameworks
Other Established Oral Options
Orlistat (Xenical) remains a non-injectable option. It generally delivers more modest weight loss compared to GLP-1-based therapies and may be limited by gastrointestinal side effects.
It may still suit selected patients who are not candidates for injectable medical weight loss treatments in the UAE.
Quick summary (2026):
-
Most effective current injectable: Tirzepatide
-
Most established GLP-1: Semaglutide
-
First oral GLP-1 pill: Approved in US, UAE timeline pending
-
Strong pipeline through 2028
What’s Coming Next (2026–2028 Pipeline)
The obesity-medicine pipeline is expanding rapidly.
CagriSema (Cagrilintide + Semaglutide)
In the REDEFINE-1 trial (obesity population), Novo Nordisk reported around 22.7% average weight loss at 68 weeks.
New February 2026 data in people with type 2 diabetes showed greater weight loss than semaglutide alone, though total percentage reduction differed between populations.
This combination may represent the next evolution in high-efficacy injectable therapy.
Orforglipron (Eli Lilly) – Daily GLP‑1 Pill
Orforglipron is an investigational oral GLP-1 designed to deliver injection-like results in tablet form.
As of 2026, it remains under regulatory review. If approved, it could significantly expand the oral weight loss pill UAE market.
Amycretin (Novo Nordisk)
Amycretin targets GLP-1 and amylin pathways. Early data have shown notable weight-loss potential, and development is progressing into later-stage trials.
It may be particularly relevant for patients requiring higher total weight reduction.
Survodutide (GLP‑1 + Glucagon)
Survodutide combines appetite suppression with increased energy expenditure. Phase 3 programmes are underway.
If successful, it could add another advanced injectable option within the next few years.
Retatrutide ( Triple Agonist)
Retatrutide targets GLP-1, GIP, and glucagon receptors. Phase 3 trials continue in 2026.
If outcomes remain strong, this could become one of the most powerful weight loss medications globally later in the decade.
MariTide (Monthly or Less‑Frequent Dosing)
MariTide aims to deliver potent weight loss with monthly—or potentially less frequent—dosing.
Phase 2 data showed up to ~20% average weight loss at 52 weeks. Phase 3 trials are underway.
Less frequent dosing may improve adherence for long-term patients
HU6 (Metabolic / Liver-Focused Therapy)
HU6 is being investigated as an oral therapy targeting metabolic and liver-fat pathways.
It may become especially relevant for patients with fatty-liver-related metabolic disease.
Where Gastric Balloons Still Fit in the UAE
Despite powerful medications, gastric balloons remain relevant in Dubai and Abu Dhabi.
They may suit patients who:
• Prefer a time-limited device rather than long-term medication
• Need appetite reset and portion control support
• Are unsuitable for GLP-1-based therapy
Typical outcomes range between 10–15% total body weight loss over 6–12 months, with stronger results when structured aftercare is provided.
Safety, Supply, & Why Medical Supervision Matters
As demand for weight loss medications in the UAE rises, regulators globally are tightening oversight of:
• Unlicensed prescribing
• Compounded “copies”
• Online sourcing
Patients should prioritise:
• Licensed UAE clinicians
• Authentic pharmaceutical supply chains
• Structured follow-up
Medical supervision is critical to managing side effects and protecting long-term health.
Final Thoughts: The Direction of Weight Loss Medicine in 2026
2026 represents a step-change in obesity medicine:
• Stronger injectable therapies
• The first true oral GLP-1 weight-loss option in major markets
• Rapid expansion of next-generation pipeline treatments
For patients in Dubai and Abu Dhabi, the best results will continue to come from matching the right weight loss medication in the UAE to the right patient—combined with nutrition, movement, and ongoing medical monitoring.
Considering Weight Loss Medications in the UAE?
If you are exploring weight loss medications in the UAE — whether GLP-1 injections, oral therapies, or combination treatments — suitability depends on your medical history, BMI, metabolic profile, and long-term goals.
A structured clinical assessment helps determine:
-
Whether medication is appropriate
-
Which option is safest
-
How to manage side effects properly
-
Whether non-surgical or surgical alternatives may be more suitable
Patients in Dubai and Abu Dhabi should prioritise licensed medical supervision and structured follow-up for safe, sustainable results.
